{
  "source": "PA-Notification-Gavreto.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1336-5\nProgram Prior Authorization/Notification\nMedication Gavreto® (pralsetinib)\nP&T Approval Date 11/2020, 11/2021, 11/2022, 11/2023, 11/2024\nEffective Date 2/15/2025\n1. Background:\nGavreto (pralsetinib) is a kinase inhibitor indicated for the treatment of adult patients with\nmetastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer\n(NSCLC).\nGavreto is also indicated for adult and pediatric patients 12 years of age and older with advanced or\nmetastatic RET fusion-positive thyroid cancer who require systemic therapy and who are\nradioactive iodine-refractory (if radioactive iodine is appropriate). This indication is approved\nunder accelerated approval based on overall response rate and duration of response. Continued\napproval for this indication may be contingent upon verification and description of clinical benefit\nin confirmatory trial(s). The National Cancer Comprehensive Network (NCCN) also recommends\nuse of Gavreto in hepatobiliary cancers that is RET gene fusion positive.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of 19\nyears, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or under\nsome circumstances. Some states also mandate usage of other Compendium references. Where such\nmandates apply, they supersede language in the benefit document or in the notification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Gavreto will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Non-Small Cell Lung Cancer (NSCLC)\n1. Initial Authorization\na. Gavreto will be approved based on all of the following criteria:\n(1) Diagnosis of non-small cell lung cancer (NSCLC)\n-AND-\n© 2024 UnitedHea",
    "n-Small Cell Lung Cancer (NSCLC)\n1. Initial Authorization\na. Gavreto will be approved based on all of the following criteria:\n(1) Diagnosis of non-small cell lung cancer (NSCLC)\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\n(2) Disease is one of the following:\n(a) Recurrent\n(b) Advanced\n(c) Metastatic\n-AND-\n(3) Presence of RET rearrangement positive tumors\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Gavreto will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Gavreto therapy\nAuthorization will be issued for 12 months.\nB. Thyroid Carcinoma\n1. Initial Authorization\na. Gavreto will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Diagnosis of one of the following:\ni. Follicular carcinoma\nii. Oncocytic carcinoma\niii. Papillary carcinoma\n-AND-\n(b) One of the following:\ni. Unresectable locoregional recurrent disease\nii. Persistent disease\niii. Metastatic disease\n-AND-\n(c) Disease is RET gene-fusion positive\n-AND-\n(d) Disease is not amenable to radioactive iodine therapy\n© 2024 UnitedHealthcare Services, Inc.\n2\n-OR-\n(2) All of the following:\n(a) Diagnosis of medullary carcinoma\n-AND-\n(b) One of the following:\ni. Disease is recurrent, persistent, or progressive\nii. Disease is symptomatic with distant metastases\n-AND-\n(c) Disease is RET-mutation positive\n-OR-\n(3) All of the following:\n(a) Diagnosis of anaplastic carcinoma\n-AND-\n(b) One of the following:\ni. Disease is stage IVA or IVB (locoregional)\nii. Disease is metastatic\n-AND-\n(c) Disease is RET gene fusion positive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Gavreto will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Gavreto therapy\nAuthorization will be issued for 12 months.\nC. Hepatobiliary Cancers\n1. Initial Authorization\na. Gavreto will be approved based on both of the following criteria:\n© 2024 UnitedHealthcare",
    "vreto therapy\nAuthorization will be issued for 12 months.\nC. Hepatobiliary Cancers\n1. Initial Authorization\na. Gavreto will be approved based on both of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n3\n(1) One of the following:\n(a) Both of the following:\ni. Diagnosis of gallbladder cancer\n-AND-\nii. Disease is one of the following\n• Unresectable\n• Resected gross residual (R2)\n• Metastatic\n-OR-\n(b) Both of the following:\ni. Diagnosis of cholangiocarcinoma\n-AND-\nii. Disease is one of the following\n• Unresectable\n• Resected gross residual (R2)\n• Metastatic\n• Resectable locoregionally advanced\n-AND-\n(2) Disease is positive for RET gene fusion mutation\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Gavreto will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Gavreto therapy\nAuthorization will be issued for 12 months.\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n4\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Gavreto [package insert]. South San Francisco, CA: Blueprint Medicines Corporation, March\n2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.ncc",
    "e.\n4. References:\n1. Gavreto [package insert]. South San Francisco, CA: Blueprint Medicines Corporation, March\n2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed September 29, 2024.\nProgram Prior Authorization/Notification – Gavreto® (pralsetinib)\nChange Control\n11/2020 New program.\n11/2021 Annual review. Added criteria for thyroid carcinoma according to label\nand NCCN compendium. Updated background and references.\n11/2022 Annual review. Updated coverage criteria to include hepatobiliary\ncancers per NCCN compendium. Added state mandate and updated\nreferences.\n11/2023 Annual review. Updated NSCLC criteria based on FDA label. Updated\nhepatobiliary cancer criteria per NCCN compendium. Updated name of\noncocytic carcinoma per NCCN nomenclature. Updated references.\n11/2024 Annual review. Updated criteria for hepatobiliary cancers based on\nNCCN guideline. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n5"
  ]
}